An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Completed · Phase 2/Phase 3

Conditions studied: Hemophilia A

In brief

This is an open-label, non-randomized, efficacy, safety and pharmacokinetic (PK) study comparing octocog alfa and rVIII-SingleChain. The study consists of three parts, a PK period (Part 1), a continuation of dosing safety and efficacy period (Part 2) and a safety, efficacy, and repeat PK period (Part 3) and also includes a surgical sub-study for subjects enrolled in Parts 2 and 3.

Key facts

Study ID

NCT01486927

Run by

CSL Behring

People needed

175

Starts

2012-02-01

Expected to finish

2014-12-01

Last updated by the study team

2016-08-09

Who can join

Age: 12 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of severe hemophilia A defined as <1% FVIII:C documented in medical records.
• Males between 18 and 65 years of age (Parts 1 and 2).
• Males between 12 and 65 years of age (Part 3).
• Subjects who have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had >150 exposure days (EDs) with a FVIII product
• Written informed consent for study participation obtained before undergoing any study specific procedures.

You may not qualify if…

• Any history of or current FVIII inhibitors
• Any first order family history of FVIII inhibitors
• Use of an Investigational Medicinal Product within 30 days prior to the first rVIII-SingleChain administration.
• Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product.
• Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.
• Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency.
• Platelet count < 100,000/µL at screening.
• Human immunodeficiency virus (HIV) positive subjects with a CD4 count < 200/mm3, in their medical history or at screening if available results are older than one year. (HIV positive subjects may participate in the study and antiviral therapy are permitted, at the discretion of the Investigator).
• Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment.
• Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) values > 5 times (x) the upper limit of normal (ULN) at Screening.
• Subjects with serum creatinine values > 2 x ULN at Screening.
• Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1.
• Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Day 1.

Where it is running

• Study Site — San Diego, California, United States
• Study Site — Aurora, Colorado, United States
• Study Site — Hartford, Connecticut, United States
• Study Site — Miami, Florida, United States
• Study Site — Chicago, Illinois, United States
• Study Site — New Orleans, Louisiana, United States
• Study Site — Houston, Texas, United States
• Study Site — Milwaukee, Wisconsin, United States
• Study Site — Nedlands, Australia
• Study Site — Perth, Australia
• Study Site — Graz, Austria
• Study Site — Vienna, Austria
• Study Site — New Brunswick, Canada
• Study Site — Hradec Králové, Czechia
• Study Site — Berlin, Germany
• Study Site — Berlin, Germany
• Study Site — Bonn, Germany
• Study Site — Giessen, Germany
• Study Site — Hamburg, Germany
• Study Site — Hanover, Germany
• Study Site — Heidelberg, Germany
• Study Site — Debrecen, Hungary
• Study Site — Florence, Italy
• Study Site — Milan, Italy
• Study Site — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.